Aprotinin impairs endothelium-dependent relaxation in rat aorta and inhibits nitric oxide release from rat coronary endothelial cells

Cardiovascular Research

Volumn 50, Issue 3, 2001, Pages 589-596

  Ülker, Sibel ^a   Çinar, Mehtap G ^a   Bayraktutan, Ulvi ^b   Evinç, Akgün ^a  

^a EGE UNIVERSITY   (Turkey)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Arteries; Cell culture isolation; Endothelial function; Nitric oxide; Vasoconstriction dilation

Indexed keywords

ACETYLCHOLINE; APROTININ; ARGININE; CALCIMYCIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NITRITE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; POTASSIUM CHLORIDE; SERINE PROTEINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTERY CONSTRICTION; ARTICLE; BLOOD VESSEL REACTIVITY; CELL ISOLATION; CONTROLLED STUDY; CORONARY ARTERY; ENDOTHELIUM CELL; HEART PERFUSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RESTENOSIS; SMOOTH MUSCLE RELAXATION; THORACIC AORTA;

ANIMALS; AORTA, THORACIC; APROTININ; CELL CULTURE TECHNIQUES; CULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HEMOSTATICS; MALE; NITRIC OXIDE; NITRITES; PHENYLEPHRINE; RATS; RATS, WISTAR; SERINE PROTEINASE INHIBITORS; VASOCONSTRICTION; VASODILATION;

EID: 0034997704     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(01)00268-1     Document Type: Article

References (24)

1. Bidstrup B., Royston D., Sapsford R., Taylor K. Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin (Trasylol). J Thorac Cardiovasc Surg. 97:1989;364-372.
2. Levi M., Cromheecke M.E., de Jonge E., et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet. 354:(9194):1999;1940-1947.
3. Cosgrove D.M. III, Heric B., Lytle B.W., et al. Aprotinin therapy for reoperative myocardial revascularisation: a placebo-controlled study. Ann Thorac Surg. 54:1992;1031-1038.
4. 2 in cultured human umblical vein endothelial cells. J Thorac Cardiovasc Surg. 104:1992;654-658.
5. Havel M.P., Griesmacher A., Weigel G., et al. Aprotinin increases release of von Willebrand factor in cultured human umblical vein endothelial cells. Surgery. 112:1992;573-577.
6. Rodeberg D.A., Chaet M.S., Bass R.C., Arkovitz M.S., Garcia V.F. Nitric oxide: an overview. Am J Surg. 170:1995;292-303.
7. Ruvolo G., Greco E., Speziale G., Tritapepe L., Marino B. Nitric oxide formation during cardiopulmonary bypass. Ann Thorac Surg. 57:1994;1055-1056.
8. Hill G.E. Cardiopulmonary bypass-induced inflammation: is it important? J Cardiothorac Vasc Anesth. 12:(2 Suppl 1):1998;21-25.
9. Hill G.E., Springall D.R., Robbins R.A. Aprotinin is associated with a decrease in nitric oxide production during cardiopulmonary bypass. Surgery. 121:1997;449-455.
10. Bruda N.L., Hurlbert B.J., Hill E.G. Aprotinin reduces nitric oxide production in vitro and in vivo in a dose-dependent manner. Clin Sci. 94:1998;505-509.
11. Hill G.E., Robbins R.A. Aprotinin but not tranexamic acid inhibits cytokine-induced inducible nitric oxide synthase expression. Anesth Analg. 84:1997;1198-1202.
12. Hill G.E., Taylor J.A., Robbins A.R. Differing effects of aprotinin and ε-aminocaproic acid on cytokine-induced inducible nitric oxide synthase expression. Ann Thorac Surg. 63:1997;74-77.
13. Venturini G., Colasanti M., Ascenzi P. Aprotinin, the first competitive protein inhibitor of NOS activity. Biochem Biophys Res Commun. 249:1998;263-265.
14. Piper H.M., Spahr R., Mertens S., Krytzfeldt A., Watanabe H. Microvascular endothelial cells from the heart. Piper H.M. Cell culture techniques in heart and vessel research. 1990;158-177 Springer, Berlin.
15. Bories P.N., Bories C. Nitrate determination in biological fluids by an enzymatic one-step assay with nitrate reductase. Clin Chem. 41:(6):1995;904-907.
16. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J Biol Chem. 193:1951;265-275.
17. Egleme C., Godfraind T., Miller R.C. Enhanced responsiveness of rat isolated aorta to clonidine after removal of endothelial cells. Br J Pharmacol. 81:1984;16-21.
18. 2+-independent activation of the endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 96:1999;1123-1128.
19. Moncada S., Palmer R.M.J., Higgs E.A.A. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev. 43:(2):1991;109-142.
20. Schini-Kerth V.B., Boese M., Busse R., Fisslthaler B., Mülsch A. N-α-Tosyl-L-lysine chloromethylketone prevents expression of iNOS in vascular smooth muscle by blocking activation of NF κB. Arterioscler Thromb Vasc Biol. 17:1997;672-679.
21. Harrison D.G., Sayegh H., Ohara Y., Inoue N., Venema R.C. Regulation of expression of the endothelial cell nitric oxide synthase. Clin Exp Pharmacol Physiol. 23:1996;251-255.
22. Westaby S. Aprotinin in perspective. Ann Thorac Surg. 55:1993;1033-1041.
23. Hardy J.F., Desroches J. Natural and synthetic antifibrinolytics in cardiac surgery. Can J Anaesth. 39:1992;353-365.
24. Jahr J.S., Kaye A.D., Kang B., Feng C.J., Nossaman B.D. Analysis of aportinin on the mean arterial pressure, carotid artery blood flow, and hindlimb vascular resistance in the live rat, and pulmonary vascular resistance in the isolated perfused rat lung. J Med. 26:(1-2):1995;31-42.